{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:53:12Z","timestamp":1776855192670,"version":"3.51.2"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":2687,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.breast.2012.01.015","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T02:13:38Z","timestamp":1329358418000},"page":"309-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab"],"prefix":"10.1016","volume":"21","author":[{"given":"Silvia","family":"Dellapasqua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Bagnardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Sandri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Pastrello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cancello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Montagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Luini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aron","family":"Goldhirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2012.01.015_bib1","series-title":"Abstr 10th Int Congr on anti-cancer treatment","first-page":"45","article-title":"What is the optimal duration of chemotherapy in advanced breast cancer?","author":"Buzdar","year":"2000"},{"key":"10.1016\/j.breast.2012.01.015_bib2","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM198712103172402","article-title":"Improving the quality of life during chemotherapy for advanced breast cancer","volume":"317","author":"Coates","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2012.01.015_bib3","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/S0959-8049(97)00396-1","article-title":"A\u00a0randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast","volume":"33","author":"Gregory","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2012.01.015_bib4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0140-6736(90)90277-C","article-title":"Comparison of short-term and continuous chemotherapy (mitoxantrone) for advanced breast cancer","volume":"335","author":"Harris","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2012.01.015_bib5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199111073251904","article-title":"Interrupted versus continuous chemotherapy in patients with metastatic breast cancer","volume":"325","author":"Muss","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"6801","key":"10.1016\/j.breast.2012.01.015_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.breast.2012.01.015_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.breast.2012.01.015_bib8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrc905","article-title":"Clinical translation of angiogenesis inhibitors","volume":"2","author":"Kerbel","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.breast.2012.01.015_bib9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"10.1016\/j.breast.2012.01.015_bib10","first-page":"6938","article-title":"Protracted low-dose effects on human endothelial cell proliferation and survival in\u00a0vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs","volume":"62","author":"Bocci","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2012.01.015_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00001813-200302000-00005","article-title":"Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies","volume":"14","author":"Wenzel","year":"2003","journal-title":"Anti-Cancer Drugs"},{"issue":"30","key":"10.1016\/j.breast.2012.01.015_bib12","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","article-title":"Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer","volume":"26","author":"Dellapasqua","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2012.01.015_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2012.01.015_bib14","unstructured":"http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf."},{"issue":"3","key":"10.1016\/j.breast.2012.01.015_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0169-2607(02)00017-2","article-title":"Bivariate linear mixed models using SAS proc MIXED","volume":"69","author":"Thi\u00e9baut","year":"2002","journal-title":"Comput Metods Programs Biomed"},{"key":"10.1016\/j.breast.2012.01.015_bib16","series-title":"Linear mixed models for longitudinal data","author":"Verbeke","year":"2000"},{"key":"10.1016\/j.breast.2012.01.015_bib17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.COC.0000071464.83271.08","article-title":"Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer","volume":"27","author":"Karvellas","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.breast.2012.01.015_bib18","first-page":"134","article-title":"Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers","volume":"1","author":"Sun","year":"2009","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.breast.2012.01.015_bib19","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/jnci\/88.16.1110","article-title":"Clinicopathologic and prognostic significance of an angiogenetic factor, thymidine phosphorylase, in human colorectal carcinoma","volume":"88","author":"Takebayashi","year":"1996","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2012.01.015_bib20","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2012.01.015_bib21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1248\/bpb.21.713","article-title":"Antitumor activities of a novel fluoropyrimidine, N 4-pentoxycarbonyl-5-deoxy-5-fluorocytidine (capecitabine)","volume":"21","author":"Ishikawa","year":"1998","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.breast.2012.01.015_bib22","first-page":"685","article-title":"Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts","volume":"58","author":"Ishikawa","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2012.01.015_bib23","first-page":"1063","article-title":"Prognostic role of thymidylate synthase, thymidine phosphorylase\/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer","volume":"6","author":"Van Triest","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2012.01.015_bib24","series-title":"Principles of antineoplastic drug development and pharmacology","first-page":"543","article-title":"Resistance to antimetabolites","author":"Peters","year":"1996"},{"key":"10.1016\/j.breast.2012.01.015_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2141.1972.tb03511.x","article-title":"Observations on the biochemical basis of megaloblastic anaemia","volume":"23","author":"Hoffbrand","year":"1972","journal-title":"Br J Haematol"},{"key":"10.1016\/j.breast.2012.01.015_bib26","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/cncr.23711","article-title":"Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma","volume":"113","author":"Rini","year":"2008","journal-title":"Cancer"},{"issue":"16S","key":"10.1016\/j.breast.2012.01.015_bib27","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1200\/jco.2005.23.16_suppl.9045","article-title":"Erythrocyte macrocytosis is a rather common, apparently uneventful yet unexplained finding in GIST imatinib chronic therapy","volume":"23","author":"Aliberti","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2012.01.015_bib28","first-page":"327","article-title":"In\u00a0vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2012.01.015_bib29","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1200\/JCO.2002.20.7.1711","article-title":"Thymidylate synthase levels: prognostic, predictive, or both?","volume":"20","author":"Allegra","year":"2002","journal-title":"J\u00a0Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977612000215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977612000215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:28:18Z","timestamp":1760776098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977612000215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0960977612000215"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2012.01.015","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2012.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}